sing family of new bactericidal antimicrobials, and this review attempts to narrow the gap between the busy clinician and the growing amount of literature on the subject, in such a way that he or she can choose among a varied quinolone group available in the market.

Literatura citada

1. Albrecht,R.: Development ofantibacterial agentsofthenalidixic acid type. Prog. Drug Res., 21: 99-104 (1977).

2. Al-Orainey, I.O., Bashandi, A.M. and Saeed, E.N.S.: Failure of ciprofloxacin to eradicate brucellosisin experimental aninia1s.J Chemother., 2: 380-383 (1990).

3. Anadbn, A., Martinez-Larrafiaga, M.R., Diaz M.J., Velez, C. and Bringas, P.: Pharmacokinetics of pipemidicacid in chicken after sin& intravenous and oral dosin~. '~m.J. vet. Res., 51: 17561 759 (1990). . ,

4. Anadbn, A., Martinez-Larrafiaga, M.R., Diaz, M.J.,Velez, C. and Bringas, P.: Pharmacokinetic and residue studies of quinolone compounds and olaquindox in poultry. Ann. Rech. Vet., 21 (Suppl. 1): 137s-144s (1990).

5. Bergan, T.: Qinolones. In: Antimicrobial Agents Annual 2. Edited by: Peterson, P.K.,VerhoefJ., 169-1 83. EIsmier, Amsterdam, Holland, 1987.

6. Booth, N. and McDonald, L.: Veterinary Pharmacology and therapeutics. 5th ed. Iowa State University h s , Ames, Iowa, 1982.

7. Brown,D.A.,Vooper,J., Gauze,J:]., Greco,D.S., Weise,D.W. and Brlck,J.M.: Pharmacokinetics of norfloxacin in dogs after single intravenous and single ant1 multiple oral administrations of the drug. Am..J vet. &s., 51: 1065-1 070 (1990).

8. Burkhandt, J.E., Hill, M.A., Carlton, W.W. and Kesterson,J.W.: Histologic and histochemical changes in articular cartilages of immature Beagle dogs dosed with difloxacin, a fluoroquinolo- ne. Vet. Pathol., 27: 162-1 70 (1990).

9. Chin,N.X. andNeu,H.C.: I~zViboactivityofenoxacin, aq~iinolone carboxylic acid, compared with those of norfloxacin, new P lactams, aminoglycosides, and trinietlioprim. Antimimb. Agents Chemother., 24: 754763 (1983).

10. Chin,N.X. and Neu, H.C.: Ciprofloxacin,aquinolone carboxilic acid compoundactive against aerobic bacteria. Antimimob. Agents Cl~mother., 25 319-326 (1984).

11. Christ, W., Lelinert, T. ancl lilhrich, B.: Specific toxicologic aspects of the quinolones. h. hfecl. Dis., 10 (Suppl. 1): 141s- 146s (1988).

12. Chu, D.T.W., Fernandes, P.R. and Pernet, A.G.: Synthesis and biological activityofbenzothiazolo (3,2-a) quinoloneantihacterial agent.J. Med. Chem., 29: 1531-1534 (1986).

13. C11r1,D.T.w. andFernandes,P.B.: St r~~cture activityrelationships of the fluoroquinolones. Antimicroh. Agents Cimother., 33 131- 135 (1989).

14. Cornett, J.B., Wagner, R.B., Dol>son, R.A. Wentlancl, M.P. and Bailey, D.M.: In rdtm and h rtvo antibacterial activities of the fluoroquinolone WIN 49375 (aniifloxacin). Antimimb. Agents Chemother., 27: 410 (1985).

15. Crumplin, G.C., Kenwright, P. and Hirst, T.: Investigation into the mechanism of action of the antibacterial agent norfloxacin, J. Antimimob. Chemother., 8: 251-261 (10R4).

16. Crrlmplin, G.C. and Sinith,J.T.: Nalidixic acid: An antibacterial paradox. Antimimb. Agents C/~~mother., 8: 251-261 (1975).

17. Domagala, J.M., Hanna, L.D., Heifetz, C;.L., Huff, M.P., Mich, T.F., Sanchez, P. and Solomon, M.: New structure activity relationship of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase a8say.j. Med. Chem., 29: ,704-404 (1986).

18. Dow, S.W. and Papich, M.G.: An update on antimicrobials: New uses, modifications and devrlopments. Vet. Md. , 85: 707-715 (1990).

19. Drilca, K.: Biology of bacterial cleoxiribonucleic acid topoisomerases. Mirrobiol. hl., 48: 273-289 (1984).

20. Endtz, H.P., Rujjs, G,]., Klingeren van, B.,Jansen, W.H., Rrytlen van der, T. and Mouton, R.P.: Q~~inolone in CnmpyloI)actwisola-

ted from man and poultry following the introduction of fluoro- quinolones in veterinary medicine.J Antimimb. Chemother., 27: 199-208 (1991).

21. Frame, G.M., Mann, D.D. and Lynch, M.J.:Pharmacokinetc of quinolone antibiotic danofloxacin (CP-76,136) in cattle swine and poultry. Abstracts of the 29th Interscience Conference on Antimicrobial Agentsandchemotherapy. Houston,Texas. 1989. 127-128. Omnipess. Madison, Wisconsin (1989).

22. Gargallo, D., Moros, M., Coll, R., Esteve, M., Pares, J., Xicota, M.A. and Guinea, J.: Activity of E-3846, a new fluoroquinolone anclin experimental cystitisandphyelonephritisin rats.Antimiaob. Agents Chemother., 39: 636-641 (1988).

23. Gede, K.W.: Antibacterial activity of newer quinolones and nalidiiic acid against bovine mastitis pathogens. Dt. TimamtL Wochenschr., 94: 545-548 (1987).

24. Gelleret, M: DNA topoisomerases. Ann. Rev. Biochem., 50: 87% 910 (1981).

25 Georgopapadaku, N.H., Dix, B.A., Angerhn, P., Wick, A. and Olson, G.L.: Monocyclic and tricyclic analogues of quinolones: Mechanism of action. Antimimb. Agents Chemother., 31: 614-616 (1987).

26. Giles, C.J., Grimshaw, W.T.R., Shanks, D.J. and Smith, D.C.: Efficacy of danofloxacin in the therapy of acute bacterial pneumonia in housed beef cattle. Vet. Rec., 128: 296-300 (1991).

27. Giles, C1l., Magonigle, R.A., Grimshaw, W.T.R., Tanner, A.C., Risk, J.E., Lynch, M.J. and Rice, J.R.: Clinical pharmacokinetics of parenterally administered danofloxacin in cattle. j. vet. Phannacol. Therap., 14: 400-410 (1991).

28. Cambert, M.E., Aulicino, T.M., Bouchet Du, L. and Berkowits, L.B.: Susceptibility of Nocardia astenides to new quinolone and beta-lactams. Antdm'mb. Agents Chemother., 31: 201 32014 (1987).

29. Greene, C.E.: New developments in antimicrobial therapy. Proceedings of the Tenth Annual Veterinary Medical Forum. 1992.93-96. Blacksburg,Virginia. Omnipess. Madison, Wisconsin (1992).

30. Hannan, P.C.T. and Goodwin, R.F.W.: Treatment of experimen- tal enzootic pneumonia of the pig by norfloxacin or its 6chloro analogue. h s . vet. Sci., 49: 203-210 (1990).

31. Hannan, P.C.T., O'Hanlon, P.J. and Rogers, N.H.: In vih-o evaluation of varius quinolone antibacterial agents against veterinary Mycoplasmas and porcine respiratory bacterial pathogens. Res. vet. Sci., 46: 202-211 (1989).

32. Hinz, K.T. and Rottman, S.: Studies in vivo on the efficacy of enrofloxacin against Mycoplusmagallisepticum. Avian Pathol., 19: 511-522 (1990).

33. Holmes, B., Brodgen, R.N. and Richards, D.M.: Norfloxacin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs, 30: 482-513 (1985).

34. Honston, D.M., Parent,J. andMatushek, K.: Ivermectin toxicosis in a dog..J Am. vet. med. Ass., 191: 78-80 (1987).

35. Innoue, S.J., Yamagishi, S., Nakamura, S., Furutani, Y. and Shimizu, M.: Novel nalidixic acid-resistance mutations relating to DNA-gyrase activity. In: Drug Resistance in Bacteria. Edited by: Mits~ihashi, S., 41 1-414. Thieme Stratton, New York, 1982.

36. Ito, A., Hirai, K., Inoue, M., Koga, H., Suzue, S., Irikure, T. and Misuhashi, S.: In vih-o antibacterial activity of AM-715 a new nalidixic acid analogue. Antimimob. Agents Chemother., 17: 103- 108 (19RO).

37. Jefson, M.R. ancl McGuirk, P.R.: Danofloxacin mesylate advodn (CP-76136-27), aveterinary antibacterial fluoroquinolone. Drug Futures, 129397 (1992).

38. King, A., Shannon, K. and Phillips, I.: The in vitm activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.J Antimimb. Chenwther., 13 325-331 (1984).

39. Klinge, E., Mannisto, P.T. and Mantyla, R.: Single and multiple close pharmacokinetics of pipemidic acid in normal human volunteers. Antimimb. Agents Chenwther., 26: 69-73 (1984).

40. Krueger, J.H. and Walker, G.C.: GroEL and dnaK genes of ficherichin cob' are induced by W irradiation and nalidixic acid in an htpR+ -dependent fashion. Aoc. NatL Acad. Scd., 81: 149% 1503 (1984).

41. Leysen, D.C., Haemers, A. and Pattyn, S.R.: Mycobacteria and the newquinolones. Antimimb. Agents Chemother., 33 1-5 (1989).

vet. Mdx., 24 (2) 1991 91

42. Mann, D.D. and Frame, G.M: Pharmacokinetic study of danofloxacin in cattle and swine. Am.J vet. Ra., 53: 1022-1026 (1992).

43. McGuirk, P.R.,Jefson, M.R., Mann, D.D., Elliot, N.C., Chang, P., Cicek, EP., Cornell, C.P., Gootz, T.D.. Haskell, D.L., Hindahl, M.S.,Laflewr,L.J.,Rosenfeld,M.J.,Shuyock,T.R.,Silva,A.M. and Wetter, F.H.: Synthesis and structrire-activity relationships of 7- diazabicycloalkylquinolones including danofloxacin, a new quinolone antibacterial agent for veterinary medicine. J mal. C k , 35 611-620 (1992).

44. Mevius, D.J., Breukink, H.J., Miert van, A.S.J., Kessels, B.G.F., Jobse, AS. and Smit, J.A.H.: Effects of experimentally induced Pastnrrella haemolytica infection in dairy calves on the pharmacokineticsof flumeqnine.J vet. Pharm. Ther., 14: 174-184 (1990).

45. Miyamoto, T., Matsumoto, J., Chiba, K., Egawa, H., Shibamori, K, Minamida, A., Nishimura, Y., Okada, H., Katoaka, M., Fujita, M., Hirose, T. and Nakano, J.: Synthesis and structure-activity relationshipsof 5-substituted 6, Sdifluoroquinolones, including sparfloxacin: Anew antibiotical agent with improved p0tency.J Med. Chem., 33.1645-1656 (1 990).

46. Neer, M.T.: Clinical pharmacologic features of fluoroquinolone antimicrobial drugs.J Am. vet. mrd. Ass., 193: 577-580 (1988).

47. Neer, M.T.: Cervical pain in the small breeddog. In: Proceedings of the Tenth Annual Veterinary Medical Forum. Blacksburg, Virginia. 1992.376-379. Omniprcss. Madison, Wisconsin (1992).

48. NouwsJ.F.M.,Mevius,D.J.,Vree,T.B., Baars,kM.andLa~irensen, J.: Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs. Vet. Q., 10: 156-163 (1988).

49. PCrez-Martinez, J h : Las quinolonas: Estructura quimica, meca- nismo de acci6n bactericida y perfil de farmacologia clinica. Vet. Mh., 2.3 57-66 (1992).

50. Piddock, L.J.V., Wray, C., McClaren, I. and Wise, R.: Qtiinolone resistance in Salmonella spp: Veterinary pointers. Lancet, 336: 123-125 (1990).

51. Presc0ttJ.F. and Welding, K.M.: In ~itrosusceptibility of selected veter inq bacterial pathogens to ciprofloxacin and norfloxacin. Can.J vet. h., 54: 195-1 97 (1 990).

52. Rosychuk, R.A.W.: New therapies in veterinary dermatology. In: Proceedings of the Tenth Annual Veterinary Medical Fonim. Blacksburg, Virginia. 1992. 119-124. Omnipress. Madison, Wisconsin (1992).

53. Sala, V. and Bertoldini, G.: Activity of a new quinolone (enrofloxacin) against Camjybbacterwliand Camjybbacterjejznd from pigs. Prax. vet. Milano, 10: 10-1 1 (1989).

54. Schroeder, J.: Enrofloxacin: A new antimicrobial agent. Tydskr. S. Afi vet. Vet-.., 61: 122-124 (1989).

55. Sepiurka, L.J.: Eficiencia de la enrofloxacina en la resolucibn de diversas patologias caninas y felinas. Rev. Vet. Arg., 8: 475-4'49 (1991).

56. Soback,S.,Ziv,G., Winkier,M.andSaran,A.: Efficacyofparenteral dry cow therapy for S. aunusudder infections. 1sr.J vet. Med., 45 194-195 (1990).

57. Specht,T. E. and Frederick, G.: Qriinolone inducedarthropathy in immature Equidae. J. Am. vet. med. Ass., 198: 516-517 (1991).

58. Sumano, H.: Farmacologia Clinica en Bovinos. Fac. de Med. Vet. y Zoot., Universidad Nacional Autbnoma de Mexico, Mbico, D.F., 1990.

59. Sumano, H. y Ocampo, L.: Farmacologia Veterinaria. McGrau Hill, Mexico, D.F., 1987.

60. Takahashi, I.,Yoshida,T., Honma, Y. and Saito, E.: Comparison of the susceptibility of Haemophilw PrcragaUinarum to ofloxacin and other existing antimicrobial agents.J Jpl. vet. med. Ass., 4 3 187-191 (1990).

61. Tulkens, P.M.: Target drugs for the treatment of intracellular infections. In: New Insights Into the Pathogenesis of Mastitis. Edited by: Buwenich, C., Vandeputte-van, M.G., Hill, A.W., 163- 168. Ejksunmersiteit Gent, Gent, Belgica, 1991.

62. Vancutsem, P.M., Babish, J.G. and Schwark, W.S.: The fluoroquinolone antimicrobials: Activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell Vet., 80: 73- 186 (1990).

63. Walker, R.D., Stein, G.E., Hauptman, J.G., MacDonald, K.J., Budsber, S.C. and Rosser, E.J.: Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. Am.J vet. h., 51: 896-900 (1990).

64. Wesser, J. and Wiedemann, B.: Inhibition of R-plasmid in Eschen'chia cold by 4-quinolones. Antimimb. Agents Chenwther., 31: 531-534 (1987).

65. Williams, P.D. and Helton, D.R.: The proconvulsive activity of quinolone antibiotics in an animal model. Toxicol. Lett. (Amt.), 58: 23-28 (1991).

66. Winter, T.: Minimum inhibitory concentrations of cefacetril, enrofloxacin (Baytril) and gentamicin against mastitis streptococci. Inaugural-Dissertation. Tierantliche Fakultiit. Lud- aig-MaJn'milians-Univmitiit. Miinchen, Germany, 1988.

67. Wolfson, S.J. andHooper, C.D.:Thefluoroquinolones:Structures, mechanisms of action, resistance and spectra of activity in d m . Antimimb. Agents Chenwther., 28: 581-586 (1985).

68. Wray, C., Piddock, L:I.V. and McLaren, I.M.: Nalidixic acid- resistant salmonellasfrornanima1s.J Med. Mimbiol., 344 (1991).

69. Yancey, R.J. Jr., Sanchez, MS., Rzepkowski, RA., Chester, D.T., Barnes, R.E. and Ford, C.W.: Therapy of chronic staphylococcal mastitis. In: New Insights Into the Pathogenesis of Mastitis. Edited by: Burvenich, C., Vandeputte-van, M.G., Hill, A.W., 187- 204. Rijksuniuersiteit Gent, Ghent, Belgica, 1991.

70. Yazawa, K., Mikarni, Y. and Uno, J.: In vitm susceptibility of Nocardia spp to a new fluoroquinolone tosufloxacin (T-3262). Antimimob. Agents Chenwther., 3 3 2140-2141 (1989).

71. Ziv, G. and Marcus, M.P.H.: Clinical pharmacology of oxolinic acid in yoring dairy calves. Am.J vet. h., 37: 513-515 (1976).

72. Ziv, G., Soback, A., Kurtz, B., Glickman. A. and Whkler, M.: Concentrations of antibacterial quinolones in blood and milk. 1sr.J. vef. Med., 45: 209210 (1990).

73. Ziv. G.,Soback,A., Bor,A. andKurtz, B.: Clinical pharmacokinetics offlumequine in ca1ves.J. vet. PhannacoL, 9: 171-182 (1986).